Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (AVDL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
avdl · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Avadel Pharmaceuticals plc (AVDL) measures how much investors pay for each dollar of the company's trailing earnings. AVDL's current PE ratio of N/A is calculated by dividing its stock price of $21.64 by its TTM earnings per share of -$0.00.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%12.2x
MedianQ3 · 75%50.4x
Max
At N/A, AVDL's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Avadel Pharmaceuticals plcYou AVDL | $2.1B | N/A | — | -$0.00 |
 Alvotech ALVO | $1.3B | 51.30x | +70.0% | $0.10 |
 ANI Pharmaceuticals, Inc. ANIP | $1.8B | 20.21x | -33.0% | $3.91 |
 BGM Group Ltd. BGM | $64M | N/A | — | -$0.20 |
 Evotec SE EVO | $998M | N/A | — | -$0.28 |
 Guardian Pharmacy Services, Inc. GRDN | $2.6B | 38.14x | +26.4% | $0.79 |
 Pediatrix Medical Group, Inc. MD | $1.8B | 11.03x | -63.4% | $1.94 |
Industry Average 4 peers with valid PE | — | 30.17x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-0.51 | — | |
2023-12-31 FY2023 | — | $-2.00 | — | |
2022-12-31 FY2022 | — | $-2.29 | — | |
2021-12-31 FY2021 | — | $-1.32 | — | |
2020-12-31 FY2020 | 50.37x | $0.13 | — | |
2019-12-31 FY2019 | — | $-0.89 | — | |
2018-12-31 FY2018 | — | $-2.55 | — | |
2017-12-31 FY2017 | 4.93x | $1.66 | — | |
2016-12-31 FY2016 | — | $-1.00 | — | |
2015-12-31 FY2015 | 12.19x | $1.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Avadel Pharmaceuticals plc (AVDL) measures how much investors pay for each dollar of the company's trailing earnings. AVDL's current PE ratio of N/A is calculated by dividing its stock price of $21.64 by its TTM earnings per share of -$0.00.
Frequently asked questions
AVDL pe ratio · 6 questionsAVDL's current PE ratio is N/A as of 2026-06-08, based on a stock price of $21.64 and TTM EPS of -$0.00. Data sourced from Financial Modeling Prep via AVDL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Avadel Pharmaceuticals plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08